Evidence map›Paper›PMID 20069337›Full record

ArticleInvestigational new drugs2011

A novel structural derivative of natural alkaloid ellipticine, MDPSQ, induces necrosis in leukemic cells.

M S Shahabuddin, Mridula Nambiar, Balaji T Moorthy, Prakruthi L Naik, Bibha Choudhary, Gopal M Advirao, Sathees C Raghavan

Abstract read
PubMed Publisher
In one paragraph

Article in Investigational new drugs, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 24 citations in OpenAlex.

  1. Anticancer Effect ofMolecules (Basel, Switzerland) · 2024
    Article
  2. Article
  3. Dual-targeted therapeutic strategy combining CSC-DC-based vaccine and cisplatin overcomes chemo-resistance in experimental mice model.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2020
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

M S ShahabuddinDepartment of Biochemistry, Indian Institute of Science, Bangalore, 560 012, India.
Mridula Nambiar
Balaji T Moorthy
Prakruthi L Naik
Bibha Choudhary
Gopal M Advirao
Sathees C Raghavan
Indian Institute of Science Bangalore · INKuvempu University · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

DNA intercalating molecules are promising chemotherapeutic agents. In the present study, a novel DNA intercalating compound of pyrimido[4',5':4,5]selenolo(2,3-b)quinoline series having 8-methyl-4-(3 diethylaminopropylamino) side chain is studied for its chemotherapeutic properties. Our results showed that 8-methyl-4-(3 diethylaminopropylamino) pyrimido [4',5':4,5] selenolo(2,3-b)quinoline (MDPSQ) induces cytotoxicity in a time- and concentration-dependent manner on leukemic cell lines. Both cell cycle analysis and tritiated thymidine assays revealed that MDPSQ affects DNA replication. Treatment with MDPSQ resulted in both elevated levels of DNA strand breaks and repair proteins, further indicating its cytotoxic effects. Besides, Annexin V/PI staining revealed that MDPSQ induces cell death by triggering necrosis rather than apoptosis.

Indexed as

AlkaloidsAnnexin A5ApoptosisBiological TransportCell CycleCell DeathCell Line, TumorCell MembraneCell ProliferationCell SurvivalDNA FragmentationDNA, NeoplasmDNA RepairDNA ReplicationDrug Screening Assays, AntitumorEllipticines8-methyl-4-(3-diethylaminopropylamino)pyrimido((4',5':4,5)selenolo(2,3-b)quinoline)AlkaloidsAnnexin A5DNA, NeoplasmellipticineEllipticinesNeoplasm ProteinsOrganoselenium CompoundsPhosphatidylserinesPropidium

Identifiers

PMID20069337
OpenAlexW2056142361

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.